Unique ID issued by UMIN | UMIN000029171 |
---|---|
Receipt number | R000032481 |
Scientific Title | Retrospective case analysis of childhood Philadelphila chromosome-positive acute lymphoblastic leukemia not enrolled in clinical trials in the tyrosine kinase inhibitor era. |
Date of disclosure of the study information | 2017/09/19 |
Last modified on | 2017/09/17 00:47:26 |
Retrospective case analysis of childhood Philadelphila chromosome-positive acute lymphoblastic leukemia not enrolled in clinical trials in the tyrosine kinase inhibitor era.
JPLSG-Ph+ALL Retro
Retrospective case analysis of childhood Philadelphila chromosome-positive acute lymphoblastic leukemia not enrolled in clinical trials in the tyrosine kinase inhibitor era.
JPLSG-Ph+ALL Retro
Japan |
Philadelphila chromosome-positive acute lymphoblastic leukemia
Hematology and clinical oncology | Pediatrics | Child |
Malignancy
NO
To reveal therapeutic approach and treatment outcome of children with Philadelphila chromosome-positive acute lymphoblastic leukemia not enrolled in Japan Pediatric Leukemia Study Group (JPLSG) ALL-Ph13 clinical trial in the tyrosine kinase inhibitor era.
Others
To address (1) therapy, particularly, tyrosine kinase inhibitor concurrently administered; (2) initial response obtained by induction therapy, particularly , peripheral blood blast count on day 8, bone marrow blast count on day 15, presence or absence of complete remission after induction, and quantitative response of chimeric transcript; (3) adverse effect related treatment, particularly ones related to tyrosine kinase inhibitor; (4) yes or no of hematopoietic stem cell transplantation, and types of donor and pre-conditioning; and (5) treatment outcome on last follow-up.
Others
Explanatory
Not applicable
Induction rate defined by chemotherapeutics
Observational
1 | years-old | <= |
18 | years-old | > |
Male and Female
Those who fulfill two conditions as follows are eligible; (1) the patient who were excluded from Japan Pediatric Leukemia Lymphoma Study Group (JPLSG) ALL-B12 study because of diagnosis of Philadelphia chromosome-positive acute lymphoblastic leukemia after entry to JPLSG ALL-B12 study; (2) the patient who were not enrolled in Japan Pediatric Leukemia Lymphoma Study Group (JPLSG) ALL-Ph13 study.
Those who were considered inappropriate for entry to the current investigation by attending physician.
60
1st name | |
Middle name | |
Last name | Keisuke Kato, M.D. |
Ibaraki Children's Hospital
Division of Pediatric Hematology and Oncology, Specialty Care Service, Pediatrics
Futaba-dai 3-3-1, Mito, 311-4145, Japan
029-254-1151
keikato-ind@umin.ac.jp
1st name | |
Middle name | |
Last name | Keisuke Kato, M.D. |
Ibaraki Children's Hospital
Division of Pediatric Hematology and Oncology, Specialty Care Service, Pediatrics
Futaba-dai 3-3-1, Mito, 311-4145, Japan
029-254-1151
keikato-ind@umin.ac.jp
Japan Pediatric Leukemia Lymphoma Study Group
Ibaraki Children's Hospital
Other
NO
2017 | Year | 09 | Month | 19 | Day |
Unpublished
Preinitiation
2017 | Year | 09 | Month | 12 | Day |
2017 | Year | 09 | Month | 19 | Day |
Retrospective investigation
2017 | Year | 09 | Month | 17 | Day |
2017 | Year | 09 | Month | 17 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000032481
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |